Source Fact: Financial Supervisory Service DART / 2024-06-25
Disclosure Type: Major Management Matters Related to Investment Judgment (Amendment)
💡 3-Second Summary
Samsung Biologics has amended its Letter of Intent (LOI) for a biopharmaceutical contract manufacturing agreement worth approximately KRW 147.3B, extending the client confidentiality (withholding) deadline by one month from June 30, 2024, to July 30, 2024, per the client’s request.
📊 1. [Summary of Core Disclosure & Key Figures]
- Amended Original Disclosure: Major Management Matters Related to Investment Judgment initially submitted on June 5, 2023
- Reason for Amendment: Modification of the disclosure withholding date at the client’s request
- Contract Name: Conclusion of Letter of Intent (LOI) for Biopharmaceutical Contract Manufacturing
- Contract Amount: KRW 147,284,499,200 (Fixed amount: USD 112,534,000)
- Applied FX Rate: Fixed at KRW 1,308.80 per USD (The standard proxy rate on the initial disclosure date of June 5, 2023)
- Ratio to Revenue: 4.91% relative to the annual revenue baseline at the time of initial disclosure (KRW 3.00T)
- Counterparty: A pharmaceutical company located in the United States (Identity remaining confidential due to trade secrecy)
- Contract Period: From the LOI execution date (June 3, 2023) until the execution of the definitive formal contract
- Changes in Disclosure Withholding Expiration:
- Pre-amendment: June 30, 2024
- Post-amendment: July 30, 2024 (Extended by 1 month)
- Note: The designated contract value carries legal binding force between both parties. Upon the execution of the definitive formal contract in the future, finalized updates will be re-disclosed.
📈 2. [Expert Insight: Implications for Investors]
- Contract Validity Maintained with Timeline Adjustment: This amendment involves no alterations to the total contract value, solely shifting the disclosure withholding expiration date at the client’s request. It signals that the LOI executed in 2023 remains fully legally effective, representing a routine administrative timeline adjustment prior to the final contract steps rather than a structural shift in the deal.
- Limited Immediate Financial Volatility: Because this is an administrative timeline shift for confidentiality rather than a cancellation or value reduction, the immediate impact on the company’s current financial Fundamental remains limited.
- Investor Consideration: With the confidentiality deadline deferred to late July 2024, the specific identity of the U.S. counterparty will remain masked under trade secrecy for the time being. As noted in the filing, this deadline remains subject to further change depending on negotiations, meaning market participants should continue to monitor subsequent official disclosures tracking the potential transition into a definitive agreement.
📝 Editor’s Comment (by K-STOCK Editor)
The confidentiality window for the U.S. CMO Letter of Intent (LOI), active since mid-2023, has been deferred by one month from late June to late July. Since the contract value is explicitly stated to hold legal binding force between both parties from day one, this shift does not signal any deterioration in underlying Fundamental or a cancellation risk. Instead, it reflects a common procedural extension often seen in biopharma negotiations as corporate partners fine-tune administrative details before final execution. Shareholders should remain level-headed during this temporary extension and patiently await whether this binding framework cleanly converts into a finalized definitive supply contract notice by the adjusted deadline.
📢 Disclaimer & Source Information
Source: This content was structured and newly generated based on official data submitted to the Financial Supervisory Service’s Electronic Disclosure System (DART).
Investment Risk Notice: This information is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial liabilities rest entirely with the investor.
Contact: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.
🔥 Bulls vs Bears, drop your analysis in the comments!
